Linzey et al. report a case of a 10-year-old patient with thalamic oligodendroglioma harboring FGFR3-PHGDH fusion who responded to treatment with the tyrosine kinase inhibitor ponatinib [75]. This evidence concerns the gene FGFR3 and oligodendroglioma.